PubMed Health⌕ Search

PubMed · 16610769

HuCNS-SC (StemCells).

Abstract

HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 U.S. Food and Drug Administration approval of StemCells' investigational new drug application.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Philippe Taupin. 2006. HuCNS-SC (StemCells).. https://pubmed.ncbi.nlm.nih.gov/16610769/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome.

Restless legs syndrome (RLS) can occur as a primary disorder, with no apparent cause other than a possible genetic predisposition, or as a secondary condition, most commonly related to iron deficiency, pregnancy, or end-stage renal disease. Recent studies have identified 2 different phenotypes of RLS based on age at onset of symptoms. Persons whose RLS symptoms start at an earlier age (<45 years) are more likely to have a family history of RLS and tend to have a more slowly progressive development of the disorder compared with individuals who have later onset of symptoms. In the past, our ability to determine either prevalence or population factors associated with increased occurrence of RLS has been limited. However, 4 different diagnostic criteria have been established. Familiarity with diagnostic criteria and clinical characteristics are essential for diagnosis and appropriate treatment, if required.

Central Nervous System↗